{
  "id": "56e844c442442bac75000002",
  "type": "summary",
  "question": "When is the protein NFL a biomarker?",
  "ideal_answer": "Neurofilament light protein (NFL), may be released into the cerebrospinal fluid (CSF) during pathological processes in the central nervous system (CNS).\nNeurofilament light chain is a prognostic biomarker in neurological disorders such as amyotrophic lateral sclerosis, frontotemporal degeneration, axonal injury, late-onset cerebellar ataxia, multiple sclerosis and head trauma.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/24571714",
    "http://www.ncbi.nlm.nih.gov/pubmed/24479774",
    "http://www.ncbi.nlm.nih.gov/pubmed/24242746",
    "http://www.ncbi.nlm.nih.gov/pubmed/24073237",
    "http://www.ncbi.nlm.nih.gov/pubmed/23529999",
    "http://www.ncbi.nlm.nih.gov/pubmed/16894110",
    "http://www.ncbi.nlm.nih.gov/pubmed/24935984",
    "http://www.ncbi.nlm.nih.gov/pubmed/17290105",
    "http://www.ncbi.nlm.nih.gov/pubmed/25934855",
    "http://www.ncbi.nlm.nih.gov/pubmed/24523921",
    "http://www.ncbi.nlm.nih.gov/pubmed/23827424",
    "http://www.ncbi.nlm.nih.gov/pubmed/25192482",
    "http://www.ncbi.nlm.nih.gov/pubmed/21197541",
    "http://www.ncbi.nlm.nih.gov/pubmed/23763388",
    "http://www.ncbi.nlm.nih.gov/pubmed/22496755",
    "http://www.ncbi.nlm.nih.gov/pubmed/26273687",
    "http://www.ncbi.nlm.nih.gov/pubmed/20132991",
    "http://www.ncbi.nlm.nih.gov/pubmed/24941067",
    "http://www.ncbi.nlm.nih.gov/pubmed/23718879",
    "http://www.ncbi.nlm.nih.gov/pubmed/14694036",
    "http://www.ncbi.nlm.nih.gov/pubmed/17596713"
  ],
  "snippets": [
    {
      "text": "Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25934855",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CSF neurofilament light chain reflects corticospinal tract degeneration in ALS.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26273687",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Raised neurofilament light chain protein (NfL) in cerebrospinal fluid (CSF) is thought to reflect axonal damage in a range of neurological disorders.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26273687",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24935984",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Detection of neurofilament-H in serum as a diagnostic tool to predict injury severity in patients who have suffered mild traumatic brain injury.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25192482",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Cerebrospinal fluid (CSF) neurofilament light chain (NfL) concentration is elevated in neurological disorders, including frontotemporal degeneration (FTD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24242746",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We examined axonal injury in HIV-1 patients by measuring the light subunit of neurofilament protein (NFL) in CSF with a novel, sensitive method.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24523921",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "FL appears to be a sensitive biomarker of subclinical and clinical brain injury in HIV and warrants further assessment for broader clinical use.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24523921",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Analysis of MBP, NFL and GFAp provides direct means to measure tissue damage and is a useful addition to our methods for evaluation of MS.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24571714",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " The association of prolonged CSF NFL increase in boxers with impairment of processing speed is an interesting observation, which needs to be verified in larger studies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24941067",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "neurofilament light chain (NfL) levels in CSF of relapsing remitting (RR) patients with MS were normalized by natalizumab treatment",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23763388",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Our results suggest that NfL is superior over NfH(SMI) (35) as therapeutic biomarker and is a promising candidate to measure neuroaxonal damage in MS treatment trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23763388",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Increased neurofilament light chain blood levels in neurodegenerative neurological diseases.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24073237",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Our data supports further longitudinal studies of serum NfL in neurodegenerative diseases as a potential biomarker of on-going disease progression, and as a potential surrogate to quantify effects of neuroprotective drugs in clinical trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24073237",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " We confirmed and expanded upon previous findings regarding neurofilaments as quantitative markers of neurodegeneration",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23529999",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CSF T-tau, GFAP, and NFL are differently altered across different neurologic diseases in children",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23827424",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23718879",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "he marked NFL elevation in some but not all FTD cases is likely to reflect the different underlying pathologies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23718879",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "High levels of NFL also correlated with the presence of an AD biomarker pattern defined by A\u03b242/P-tau and T-tau. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24479774",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Increased CSF levels of T-tau, NFL, GFAP, and S-100B in>80% of the boxers demonstrate that both the acute and the cumulative effect of head trauma in Olympic boxing may induce CSF biomarker changes that suggest minor central nervous injuries. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22496755",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "eurofilament light protein (NFL), may both be released into the cerebrospinal fluid (CSF) during pathological processes in the central nervous system (CNS). We investigated GFAP and NFL levels in CSF as possible biomarkers for progression in multiple sclerosis (MS). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21197541",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A CSF profile with higher levels of NFL, Abeta42, and CSF/serum albumin ratio may indicate neuropathological and vascular events in depression etiology.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20132991",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " At present we cannot recommend CSF NfH and NfL levels for use as a screening test in the diagnosis of dementia because of the rather small effect size. However, both neurofilament proteins may be of value for targeted investigation of some patients with FTLD, SVD and AD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17596713",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Differences in CSF biomarker profiles might reflect differential involvement of neurofilaments and tau in FTD and EAD. The subgroup of FTD patients with high CSF neurofilament levels may have a different neuropathological substrate and future studies addressing this specific issue are needed.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17290105",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Increased levels of neurofilament light chain and tau and decreased levels of 3-methoxy-4-hydroxyphenylethyleneglycol were associated with high accuracy levels in differentiating the cerebellar subtype of multiple-system atrophy from idiopathic late-onset cerebellar ataxia (LOCA). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16894110",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Increased level of NFL is a general feature of MS, indicating continuous axonal damage during the entire course of the disease with the most profound damage during acute relapses. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/14694036",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/14694036",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": []
}